Gene‑edited HPSCs programmed to make therapeutic antibodies and proteins show long‑lasting, boostable immunity in mouse models.

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...

New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease, a genetic blood disorder with few curative options. Conducted as part of the ...

A review in Glycoscience & Therapy summarizes advances in selective editing of N-glycan signals on living cell surface via the LCS‑NGS technology platform. It focuses on enzyme‑based strategies ...

Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment ...

Durable expression of anti-sickling fetal hemoglobin and reduction in sickle hemoglobin ob ...

New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease, a genetic blood disorder with few curative options. After research conducted as ...

Researchers at the MRC Laboratory of Medical Sciences (LMS) and Imperial College London have identified an overworked cog in ...